Clinical Trial Update: Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of Orvepitant for chronic cough in idiopathic pulmonary fibrosis; study completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Orvepitant (Orvepitant)

Snippet

Sponsor: Nerre Therapeutics Ltd. | Conditions: Cough, Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2025-11-10